AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03665194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortexolone 17α-propionate solution
Description: Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
Study NCT03665194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT00744679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
Study NCT02367872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablet
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Given PO
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT02787070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQ supervised
Study NCT02787070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQ unsupervised
Study NCT01512290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
Study NCT01512290 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
Study NCT04401527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite
Description: Continuous intravenous infusion of Sodium Nitrite Injection
Study NCT04401527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Continuous intravenous infusion of Normal Saline
Study NCT00662870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)
Description: 0.5 mL, Intramuscular
Study NCT00662870 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel: DTaP-IPV/Hib
Description: 0.5 mL, Intramuscular
Study NCT02652429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Study NCT03380949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid administration (remifentanil) in intervention group
Description: Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
Study NCT03380949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Opioid administration (remifentanil) in control group
Description: Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
Study NCT01183962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin D
Description: Vitamin D 3000 IU daily
Study NCT01183962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No medication
Description: No intervention
Study NCT01965548 — intervention group
Intervention type: PROCEDURE
Intervention: Treatment of splenic injury
Description: There are four possible treatments of splenic injury in this study:~* splenectomy~* splenic artery embolisation~* non-operative management~* any combination of the three treatments mentioned
Study NCT02240498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
Study NCT02912611 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Education and Protocol based management
Study NCT03593408 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Administered for sedation management per hospital protocol
Study NCT03593408 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Description: Administered for sedation management per hospital protocol
Study NCT03593408 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: Administered for sedation management per hospital protocol
Study NCT03593408 — intervention group
Intervention type: DRUG
Intervention: Morphine
Description: Administered for sedation management per hospital protocol
Study NCT04290676 — intervention group
Intervention type: DRUG
Intervention: DEXYCU (dexamethasone intraocular suspension) 9%.
Description: DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).
Study NCT04229381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Undergo physical therapy
Study NCT04229381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04229381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04229381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Relaxation Therapy
Description: Undergo progressive muscle relaxation
Study NCT03047213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT02240498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% I.V. Fat Emulsion
Description: The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
Study NCT02218151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home (PCMH)
Description: Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
Study NCT02218151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
Study NCT04131218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
Study NCT00171054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Description: Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
Study NCT00171054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Description: Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
Study NCT02367872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAK-272
Description: TAK-272 tablet
Study NCT02569138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Insole
Description: hard and thin shoe insert between the foot sole and base of the footwear
Study NCT02569138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Modified Insole
Description: regular shoe insert between the foot sole and base of the footwear
Study NCT00171054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
Study NCT02240498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of optical fiber
Description: A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
Study NCT03954652 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: WGS-Diagnostic
Description: Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
Study NCT02240498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser illumination, 5 minutes
Description: Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
Study NCT02240498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser illumination, 10 minutes
Description: Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
Study NCT02240498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser illumination, 15 minutes
Description: Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
Study NCT02240498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser illumination, 20 minutes
Description: Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
Study NCT02240498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser illumination, 25 minutes
Description: Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
Study NCT02240498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser illumination, 30 minutes
Description: Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
Study NCT02240498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical spectroscopy measurement
Description: A fiber-optic probe that has undergone high-level disinfection will be advanced through the drainage catheter/needle in order to make gentle contact with the wall of the cavity. Low-intensity white light will be delivered by a tungsten halogen lamp by a single fiber within the probe, and detected by eight other fibers within the probe. Following this, low-power laser light will be delivered by a fiber-coupled laser diode at 640 nm in order to excite methylene blue fluorescence. Emitted fluorescence will similarly be collected by the eight detection fibers contained within the probe. Upon completion of these measurements, the fiber-optic probe will be withdrawn, gently wiped with sterile gauze, and returned to the procedure cart.
Study NCT01673880 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: E2006
Description: 2.5 mg, 10 mg, and 25 mg E2006 tablets
Study NCT00777218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Description: standard pediatric doses, based on body weight
Study NCT00777218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zonisamide
Description: standard pediatric dosages, based on body weight
Study NCT00777218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate
Description: standard pediatric dosages, based on body weight
Study NCT02741388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selinexor
Study NCT02741388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02741388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT02741388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT02741388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02741388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Study NCT02741388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00818675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lead-In Ridaforolimus
Description: Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
Study NCT00818675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lead-In Ridaforolimus
Description: Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
Study NCT00818675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Blinded Ridaforolimus
Description: Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
Study NCT00818675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Blinded Placebo
Description: Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
Study NCT01187719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenytoin
Description: phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
Study NCT02942329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
Study NCT02942329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
Study NCT02216825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Delayed release capsule, L. reuteri NCIMB 30242, escalated dose
Study NCT02216825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose
Study NCT04270903 — intervention group
Intervention type: DEVICE
Intervention: EPR measurement
Description: Subject put in a magnet, magnetic field sweeping around 40 mTesla. Irradiation with a wave with a frequency of 1.1 GHz. A resonator (surface coil) is put at the surface of the skin (arm). The EPR signal is recorded.
Study NCT03142022 — intervention group
Intervention type: OTHER
Intervention: No intervention - Diagnostic polysomnography at 1 year after lung transplantation
Study NCT01091727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
Study NCT01091727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum toxin A
Description: Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
Study NCT02016547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abciximab IV and thrombectomy
Study NCT02016547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
Study NCT04463511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene bag before the umbilical cord is clamped
Description: 11 x 16 (279mm x 406mm) sterile resealable PB (Resealable Polybag, Helapet Ltd, Bedfordshire, UK)
Study NCT00335231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gatifloxacin ophthalmic (ZYMAR)
Study NCT00627614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast imaging study
Description: 1. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.~2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure.
Study NCT02630199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
Study NCT02630199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
Study NCT03495544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PD-L1 expression
Description: IHC testing of PD-L1 expression level in tumor tissue samples
Study NCT01954147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1 therapy
Study NCT01954147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SC
Description: Stem cell infusion
Study NCT01954147 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT01954147 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT01383668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study NCT01383668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gold sodium thiomalate
Description: Given IM
Study NCT01383668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01383668 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Correlative studies
Study NCT01383668 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT02582255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin mOPV2
Description: Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine.
Study NCT00057122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: 300mg
Study NCT00057122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifapentine
Description: Rifapentine 900 mg
Study NCT00057122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin 600 mg
Study NCT01372982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
Study NCT01372982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
Study NCT00894374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate (Test)
Description: Oral tablet, single dose, 1 x 100 mg
Study NCT00894374 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate (Comparator)
Description: Oral tablet, single dose, 2 x 50 mg